Chae Ok Yun, Founder & CEO – GeneMedicine
Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of…
Address: 18th Floor, Hanjin Main Bld, 118, Namdaemunno-2-ga, Seoul,Republic of Korea
Tel: +82 2 772 4000
With more than thirty years of experience as one of Republic of Korea’s premiere full-service law firms, Lee & Ko has a widely recognized and long-established record of excellence in providing expert legal advice and representation to its diverse clientele in domestic and international matters involving all areas of legal practice. ith a wealth of experience in virtually all aspects of corporate law practice, Lee & Ko continues to be a highly regarded leader among Republic of Korean law firms in providing excellent legal services and creative approaches to both domestic and foreign clients doing business in or with Republic of Korea. With some of Republic of Korea’s most experienced and capable corporate law practitioners among its partners and associates, Lee & Ko’s clients receive the highest quality, the most efficient, and the most innovative legal assistance available. Lee & Ko has a distinguished and well-deserved reputation for consistently providing timely, up-to-date, accurate and reliable legal assistance with all manner of corporate legal matters, including incorporation and registration, corporate governance issues and the issuance of corporate securities.
In addition, Lee & Ko has one of Republic of Korea’s most capable, versatile and extensive legal practices in domestic and cross-border mergers and acquisitions. Lee & Ko has served as key legal counsel for innumerable foreign and domestic clients in connection with a broad range of highly complex and sensitive transactions, particularly in recent decades as the Republic of Korean corporate landscape has become more international and complex.
Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of…
Eutilex’s CEO, Byoung S. Kwon, outlines the company’s approach to cancer research, including its antibodies and CAR-T-centred pipeline and focus on unmet needs. He also explains recent partnerships in China.…
The latest healthcare and pharma news from South Korea, including SK Bioscience’s COVID-19 vaccine, Daewoong’s partnership with AstraZeneca Korea and UCI Therapeutics, Vivozon production halt and GC’s acquistion of US-based…
Chair & Founder, Regenerative Medicine Acceleration Foundation (RMAF), So Ra Park MD, PhD*, comments on the regenerative medicine ecosystem in Korea, the country’s new legislative approach to the field, and…
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP…
Boasting a pharma market size of KRW 23.2 trillion (USD 19.2 billion) for 2020, South Korea is one of Asia’s leading pharma nations. Read on for a ranking of the…
Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s…
Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand…
The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and…
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly promising R&D pipeline, and internationalisation plans. We were the…
Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their offerings through R&D. Cho also compares the challenges of the Chinese market with the potential…
See our Cookie Privacy Policy Here
